Document:

Exhibit 10.13 

 

AMENDMENT
AND CONFIRMATION AGREEMENT

 

THIS
AGREEMENT, effective December 3rd, 2015, by and among KNIGHT THERAPEUTICS (BARBADOS) INC. (“Knight”),
a corporation incorporated under the laws of Barbados, NOMAD CHOICE PTY LTD. (“Nomad”), a corporation
formed under the laws of Australia, and SYNERGY CHC CORP. (“Synergy”), a corporation formed under the
laws of the State of Nevada, and BREAKTHROUGH PRODUCTS, INC. (“Breakthrough”), a corporation formed under the
laws of Delaware.

 

WHEREAS
Synergy and Knight are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended,
supplemented or restated from time to time (the “DLS Agreement”);

 

WHEREAS
pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named Knight its exclusive distributor of
Licensed Products in the Territory;

 

WHEREAS
Synergy has acquired all of the shares of Nomad effective November 16, 2015 and, as and from that date, Nomad became an Affiliate;

 

WHEREAS
Synergy has acquired all of the shares of Breakthrough effective November 12, 2015 and as and from that date, Breakthrough became
an Affiliate;

 

WHEREAS
the parties wish to confirm that the terms and conditions of the DLS Agreement apply to Nomad and Breakthrough effective from the
dates each became an Affiliate;

 

WHEREAS
the parties wish to confirm certain amendments to the DLS Agreement;

 

NOW
THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree
as follows:

 

	1	DEFINITIONS
	 	 
	1.1	Definitions.
    Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.
	 	 
	2	GRANT
    OF RIGHTS
	 	 
	2.1	Each
    of Nomad and Breakthrough hereby confirms that it is subject to the terms and conditions of the DLS Agreement, as hereby amended,
    as if it were an original signatory thereto.
	 	 
	2.2	The
    DLS Agreement is hereby amended by replacing the definition of “Licensed Product” as follows:

 

“(i)
with respect to Synergy means FocusFactor, FocusFactor Kids, Synergy Strips and all Improvements thereto, and (ii) with respect to Nomad,
Breakthrough and any other Subsidiary of Synergy means all of the their present and future products (including with respect to Nomad
“Flat Tummy Tea” and with respect to Breakthrough “urgentRX”)”.

 

	2.3	The
    DLS Agreement is hereby amended by replacing the definition of “Territory” as follows:

 

“Territory
(i) means Canada, Israel, Romania, Russia and each of the countries within Sub-Saharan Africa.”

 

	2.4	The
    DLS Agreement is hereby amended by deleting (i) Section 11 thereof and (ii) all references in the DLS Agreement to the defined term
    “Additional Territory”.
	 	 
	2.5	Section
    9.3 of the DLS Agreement is deleted and replaced with the following:

 

“9.3
Termination of Knight. Knight may terminate this Agreement in whole or in part (including with respect to a particular Licensed
Product and/or Territory or a particular Territory in respect of a particular Licensed Product) by notice in writing given not less than
sixty (60) days prior to the intended termination date.”

 

    	 

    	 

    

 

	3	OTHER
    PROVISIONS
	 	 
	3.1	Waiver.
    No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted
    hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances.
	 	 
	3.2	Severability.
    In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain
    in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule
    of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed
    to be modified to conform with such statute or rule of law.
	 	 
	3.3	Governing
    Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination
    hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws
    of the State of New York.
	 	 
	3.4	Counterparts.
    This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall
    become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
	 	 
	3.5	Time
    of Essence. Time shall be of the essence of this Agreement and of each provision hereof.

 

    	 

    	 

    

 

In
witness whereof, the parties have signed this Agreement.

 

	 	KNIGHT THERAPEUTICS (BARBADOS) INC.

 

	 	By:	/s/
    Michael Loustric
	 	Name:	Michael
    Loustric
	 	Title:	President

 

	 	NOMAD CHOICE PTY LTD.

 

	 	By:	/s/
    Jack Ross
	 	Name:	Jack
    Ross
	 	Title:	Chief
    Executive Officer

 

	 	SYNERGY CHC CORP.

 

	 	By:	/s/
    Jack Ross
	 	Name:	Jack
    Ross
	 	Title:	Chief
    Executive Officer

 

	 	BREAKTHROUGH PRODUCTS, INC.

 

	 	By:	/s/
    Jack Ross
	 	Name:	Jack
    Ross
	 	Title:	Chief
    Executive OfficerExhibit
10.14 

 

Settlement
and Release AGREEMENT

 

This
Settlement and Release Agreement (“Agreement”) by and between Synergy CHC Corp., a Nevada corporation (“Releasor”),
the former shareholders (the “Shareholders”) of Breakthrough Products, Inc., a Delaware corporation (the “Company”),
URX ACQUISITION TRUST, a Delaware statutory trust (the “Trust”), on its own behalf and as the representative
of the Shareholders, David T. Leyrer (“Leyrer”), Michael Valentino (“Valentino”),
Ron Fugate (“Fugate”), and Randall Kaplan (“Kaplan”, and collectively with Leyrer,
Valentino, Fugate, the “Former Directors”) is dated and effective as of the 17th day of December,
2015.

 

WHEREAS,
the Company, the Trust, Jordan Eisenberg, the former chief executive officer of the Company and a Shareholder, the Shareholders and Releasor
are parties to that certain Stock Purchase Agreement (the “SPA”) dated November 12, 2015 (capitalized terms
used herein but not otherwise defined have the meaning ascribed to them in the SPA);

 

WHEREAS,
pursuant to the terms of the SPA, Releasor acquired all outstanding shares of capital stock of the Company (the “Transaction”);

 

WHEREAS,
pursuant to the terms of the SPA, the Shareholders, the Company and the Trust made certain representations and warranties to Releasor
regarding, among other things, the financial condition of the Company and the Company’s outstanding liabilities and obligations
to third parties;

 

WHEREAS,
following the Transaction, Releasor discovered certain irregularities in the financial information of the Company as well as conflicting
information regarding the Company’s liabilities and obligations to third parties from what was previously provided by the Company;

 

WHEREAS,
Releasor made a claim for indemnification against the Shareholders and the Trust pursuant to Section 8 of the SPA (the “Claim”);

 

WHEREAS,
Releasor and the Trust, on its own behalf and on behalf of the Shareholders, have reached an agreement to resolve the Claim to the mutual
satisfaction of all parties and wish to document such settlement in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows:

 

1.
Settlement Payments.

 

	 	a.	The
    Trust will return Three Million (3,000,000) shares of Releasor’s common stock to Releasor. Upon execution of this Agreement,
    the Trust will return the certificate representing the Equity Consideration to Releasor’s transfer agent, VStock Transfer,
    with instructions to transfer Three Million (3,000,000) shares to Releasor and return a new certificate to the Trust for the balance
    of Three Million (3,000,000) shares of Releasor’s common stock.
	 	 	 
	 	b.	The
    time period under which Royalty Consideration is payable to the Trust by Releasor under the SPA is reduced from seven (7) years to
    five (5) years.
	 	 	 
	 	c.	Releasor
    will issue a warrant in the form of Exhibit A to the Trust.

 

    	 

    	 

    

 

2.
Releases.

 

	 	a.	Release
    of the Trust and Shareholders by Releasor. Except as set forth in Section 3 of this Agreement, in exchange for the payments
    outlined above, Releasor, on its own behalf and on behalf of its Affiliates, directors, officers, managers, employees, agents, representatives,
    successors, and assigns, forever releases and discharges the Trust and its trustees, the Shareholders and their respective agents,
    representatives, successors, and assigns from any and all claims, demands, and causes of action of every kind and nature, whether
    known or unknown, direct or indirect, accrued, contingent or potential, which Releasor ever had or now has and which arose from the
    beginning of time until the date of this Agreement.
	 	 	 
	 	b.	Release
    of the former Directors of the Company by Releasor. Except as set forth in Section 3 of this Agreement, in exchange for
    the payments outlined above, Releasor, on its own behalf and on behalf of its Affiliates, directors, officers, managers, employees,
    agents, representatives, successors, and assigns, forever releases and discharges the Former Directors and their agents, representatives,
    heirs and assigns from any and all claims, demands, and causes of action of every kind and nature, whether known or unknown, direct
    or indirect, accrued, contingent or potential, which Releasor ever had or now has and which arose from the beginning of time until
    the date of this Agreement.
	 	 	 
	 	c.	Release
    of Releasor by the Trust and the Former Directors. Except as set forth in Section 3 of this Agreement, in exchange for
    the payments outlined above, the Trust, on its own behalf and as the representative of the Shareholders, its trustees, agents, representatives,
    successors, and assigns and the Former Directors, their heirs and assigns, forever release and discharge Releasor, its Affiliates,
    and their respective directors, officers (other than the officers of the Company prior to November 12, 2015), managers, employees
    (other than employees of the Company who were employees prior to November 12, 2015, whether or not they remained employees after
    such date), agents, representatives, successors, and assigns from any and all claims, demands, and causes of action of every kind
    and nature, whether known or unknown, direct or indirect, accrued, contingent or potential, which such parties ever had or now have
    and which arose from the beginning of time until the date of this Agreement.
	 	 	 
	 	d.	With
    respect to the foregoing releases, Releasor, Trust and the Former Directors each expressly waive any and all provisions, rights and
    benefits conferred by any law of the United States or of any country, state or territory of the United States, or principle of common
    law, which is similar, comparable, or equivalent to Section 1542 of the California Civil Code, and including Section 1542 of the
    California Civil Code which provides:

 

A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING
THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

 

3.
Future Claims. Each party to this Agreement specifically acknowledges and agrees that all rights of any party to pursue Jordan
Eisenberg and any former officers and employees of the Company (the “Company Management Team”) are specifically
reserved, except that no claim survives against Valentino notwithstanding his title as Chairman of the Company. Releasor hereby covenants
and agrees not to bring or initiate any proceeding to assert any claims, rights or remedies against the Trust, any trustee of the Trust,
any Former Director or any Shareholder (other than Shareholders who are also members of the Company Management Team) under the indemnification
provisions of the SPA or otherwise that relate in any way to the Claim, to any other potential claims under the SPA or to the Transaction;
provided, however, that all parties acknowledge and agree that any claims by Releasor against the Trust or any Shareholder
for breach of any representation or warranty contained in Sections 3 and 4(e) of the SPA are specifically preserved (the “Preserved
Claims”). For purposes of clarity, Releasor and its successors and assigns shall have no further rights to indemnification
under Section 8 of the SPA other than claims against the Company Management Team and other than the Preserved Claims.

 

4.
Authority. Each party to this Agreement, on its own behalf and on behalf of those it represents, represents and warrants to
all other parties that such party has all requisite power and authority to enter into this Agreement and to carry out its obligations
thereunder.

 

    	 

    	 

    

 

5.
Successors and Assigns. This Agreement shall inure to the benefit of and shall be binding upon the successors and assigns
of the parties hereto.

 

6.
Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by,
the laws of the State of North Carolina, United States, without giving effect to the principles of conflicts of laws thereof. The parties
hereto irrevocably consent to the jurisdiction of, the federal and state courts of the State of North Carolina located in Wake County,
North Carolina for such purpose.

 

7.
Expenses. Except as otherwise provided herein, each of the parties hereto shall pay all its own expenses in connection with
this Agreement and the transactions contemplated hereby, including, without limitation, any legal and accounting fees.

 

8.
Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body
to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions
of this Agreement shall remain in full force and effect.

 

9.
Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed
to have been duly given (i) on the date of service if served personally on the party to whom notice is to be given, or (ii) on the day
of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the
party the addresses set forth in the SPA.

 

10.
Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties
or conditions hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party
waiving compliance. Any waiver by any party of any condition, or of the breach of any provision, term, covenant, representation or warranty
contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of
any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

11.
Public Announcements. The Trust shall not make any public statement regarding this Agreement or the transactions contemplated
herein without Releasor’s prior written approval. Releasor will be required to file a Form 8-K with the U.S. Securities and Exchange
Commission regarding this Agreement

.

12.
Entire Agreement. This Agreement and the exhibits hereto contain the entire understanding between the parties hereto with
respect to the matters contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written,
with regard to such matters.

 

13.
Section and Paragraph Headings. The section and paragraph headings in this Agreement are for reference purposes only and shall
not affect the meaning or interpretation of this Agreement.

 

14.
Counterparts. This Agreement may be executed in counterparts and via .pdf, each of which shall be deemed an original, but
all of which shall constitute the same instrument.

 

15.
Independent Counsel; Mutual Drafting. Each party hereto consulted, or had the opportunity to consult, legal counsel or other
advisors of its own choosing with respect to this Agreement and fully understands the meaning and intent of, this Agreement, including,
but not limited to, the final and binding effect of this Agreement and the acknowledgments, releases, and waivers contained herein. Each
party hereto shall be deemed to have consulted and assisted with the drafting of this Agreement such that any ambiguity herein shall
not be construed in favor of one party over the other party.

 

[Signature
Page Follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Settlement and Release Agreement effective as of the day and year first above written.

 

	 	SYNERGY
    CHC CORP.
	 	 	 
	 	By:	/s/
    Jack Ross
	 	Name:	Jack
    Ross
	 	Title:	Chief
    Executive Officer

 

	 	URX
    ACQUISITION TRUST,
	 	on
    its own behalf and as representative of the Shareholders
	 	 	 
	 	KMJZ
    Investments, L.L.C., Voting Trustee
	 	 	 
	 	By:
    	/s/
    Scott Peppett
	 	Name:
    	Scott
    Peppett
	 	Title:	Authorized
    Representative
	 	 	 
	 	Arbicha
    Invesments, L.L.C., Voting Trustee
	 	By
    Arbicha, LLC, Sole Member
	 	 	 
	 	By:
    	/s/
    Randall Kaplan
	 	Name:
    	Randall
    Kaplan
	 	Title:	Manager
	 	 	 
	 	Casa
    Vicente, LLC, Voting Trustee
	 	 	 
	 	By:
    	/s/
    David Leyrer
	 	Name:
    	David
    Leyrer
	 	Title:	Manager
	 	 	 
	 	URX
    Acquisition Trustee, LLC
	 	 	 
	 	By:
    	/s/
    Michael Valentino
	 	Name:
    	Michael
    Valentino
	 	Title:	Sole
    Member

 

[Signature
Page to Settlement and Release Agreement]

 

    	 

    	 

    

 

	 	FORMER
    DIRECTORS:
	 	 
	 	David
    T. Leyrer 
	 	 
	 	/s/
    David T. Leyrer
	 	 
	 	Michael
    Valentino
	 	 
	 	/s/
    Michael Valentino
	 	 
	 	Ron
    Fugate 
	 	 
	 	/s/
    Ron Fugate
	 	 
	 	Randall
    Kaplan
	 	 
	 	/s/
    Randall Kaplan

 

[Signature
Page to Settlement and Release Agreement]

 

    	 

    	 

    

 

Exhibit
A

 

Form
of Warrant

 

[Exhibit
A to Settlement and Release Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]